Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03625687 · ClinicalTrials.gov registry record · Phase 4
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT03625687: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03625687 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03625687, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.
Interventions
- DRUG Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03625687
The ClinicalTrials.gov registry entry for NCT03625687 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks is the first listed.
NCT03625687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03625687 about?
NCT03625687 is a clinical study titled "Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant". This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 8 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.
What is the current status of trial NCT03625687?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2019-02-05. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT03625687?
The interventions under investigation include: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks (DRUG).
Who is sponsoring clinical trial NCT03625687?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.